Transdermal testosterone delivery in castrated Yucatan minipigs: Pharmacokinetics and metabolism

Journal of Controlled Release

Volumn 52, Issue 1-2, 1998, Pages 89-98

  Xing, Qing Feng ^a   Lin, Senshang ^a   W Chien, Yie ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Metabolism; Miniature swine; Pharmacokinetics; Testosterone; Transdermal

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; GONAD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOGONADISM; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CASTRATION; HUMANS; HYPOGONADISM; MALE; SKIN; SPECIES SPECIFICITY; SWINE; SWINE, MINIATURE; TESTOSTERONE;

EID: 0032473474     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00190-9     Document Type: Article

References (13)

1. G.W. Cleary, Transdermal delivery systems: a medical rationale, in: V.P. Shah, H.I. Maibach (Eds.), Topical Drug Bioavailability, Bioequivalence, and Penetration, Plenum Press, New York, 1993, pp. 17-68.
2. Physicians' Desk Reference, 50th ed., Medical Economics Company Inc., Oradell, NJ, 1996.
3. Oberle R.L., Das H., Wong S.L., Chan K.K.H., Sawchuk R.J. Pharmacokinetics and metabolism of diclofenac sodium in yucatan miniature pigs. Pharm. Res. 11(5):1994;698-703.
4. Leveque D., Peter I.D., Salmon J., Salmon Y., Elkhaili H., Kaltenbach G., Jehl F. The catheterized yucatan micropig as an animal model for experimental pharmacokinetics of anticancer drugs (Abstract). Proc. Annu. Meet. Am. Assoc. Cancer Res. 36:1995;A2136.
5. Kurihara-Bergstrom T., Woodworth M., Feisullin S., Beall P. Characterization of the yucatan miniature pig skin and small intestine for pharmaceutical applications. Lab. Anim. Sci. 36(4):1986;396-399.
6. Mazer N.A., Heiber W.E., Moellmer J.F., Meikle A.W., Stringham J.D., Sanders S.W., Tolman K.G., Odell W.D. Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. J. Control. Release. 19(3):1992;347-362.
7. N.A. Mazer, S.W. Sanders, C.D. Ebert, A.W. Meikle, Mimicking the circadian pattern of testosterone and metabolite levels with an enhanced transdermal delivery system, in: R. Gurney, H.E. Junjinger, N. Peppas, (Eds.), Pulsatile Drug Delivery: Current Applications and Future Trends, Stuttgart, Wissenshaftliche Verlagsgesellschaft mbH, 1993, pp. 73-97.
8. ® (testosterone transdermal system) product information, SmithKline Beecham Pharmaceuticals, Philadelphia, PA, 1995.
9. Lin S., Chien Y.W. A rapid and simple technique for serial/continuous sampling of blood and intravenous administration in conscious swine. Contemp. Topics. 36:1997;58-61.
10. J. Gabrielsson, D. Weiner (Eds.), Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm, Sweden, 1994, pp. 411-416.
11. PCNONLIN User Guide, 4th ed., Statistical Consultants, Inc., Lexington, KY, 1992.
12. Wagner J.G., Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J. Pharm. Sci. 52(6):1963;610-611.
13. Vermeulen A., Stoica T., Verdonck L. The apparent free testosterone concentration, an index of androgenicity. J. Clin. Endocrinol. Metab. 33(5):1971;759-767.